Growth Metrics

Solid Biosciences (SLDB) Short term Debt (2024 - 2026)

Quarterly results put Short term Debt at $3.4 million for Q1 2026, down 30.21% from a year ago — trailing twelve months through Mar 2026 was $3.4 million (down 30.21% YoY), and the annual figure for FY2025 was $9.2 million, up 192.06%.

Solid Biosciences has reported Short term Debt over the past 3 years, most recently at $3.4 million for Q1 2026.

  • Short term Debt reached $3.4 million in Q1 2026 per SLDB's latest filing, down from $9.2 million in the prior quarter.
  • Across five years, Short term Debt topped out at $9.2 million in Q4 2025 and bottomed at $3.2 million in Q4 2024.
  • Median Short term Debt over the past 3 years was $4.8 million (2025), compared with a mean of $5.2 million.
  • The largest annual shift saw Short term Debt surged 192.06% in 2025 before it plummeted 30.21% in 2026.
  • Over 3 years, Short term Debt stood at $3.2 million in 2024, then skyrocketed by 192.06% to $9.2 million in 2025, then crashed by 63.59% to $3.4 million in 2026.
  • Business Quant data shows Short term Debt for SLDB at $3.4 million in Q1 2026, $9.2 million in Q4 2025, and $6.6 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 1,384,976.65 Bn 1,384,976.64 Bn -
2 Alterity Therapeutics 777,208.84 Bn 777,208.81 Bn -
3 Legend Biotech 2,801.00 Bn 2,800.10 Bn 242.10 Mn
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn -
5 Akari Therapeutics 605.66 Bn 605.66 Bn -
6 Vertex Pharmaceuticals 110.17 Bn 102.92 Bn 2.59 Bn
7 Regeneron Pharmaceuticals 66.86 Bn 58.11 Bn 3.31 Bn
8 Evaxion A 65.12 Bn 65.10 Bn -
9 Alnylam Pharmaceuticals 39.94 Bn 36.94 Bn 959.66 Mn
10 Solid Biosciences 713.77 Mn 333.09 Mn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 3.35 Mn
Dec 31, 2025 9.20 Mn
Sep 30, 2025 6.55 Mn
Jun 30, 2025 5.70 Mn
Mar 31, 2025 4.80 Mn
Dec 31, 2024 3.15 Mn
Sep 30, 2024 3.40 Mn